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ABSTRACT
Objective: Our primary objectives were to examine adherence rates across two technologies (e-prescribing software and smart pill bottle) with cross-validation from alert-triggered messaging within the patient electronic
health record (EHR) portal and to explore the benefits and challenges faced by atrial fibrillation (AF) patients in
using a smart pill bottle.
Materials and Methods: We triangulated the rate of oral anticoagulant medication adherence among 160 AF
C Wireless Smart Pill Bottle
patients over 6 months using an EHR in combination with data from the AdhereTechV
and SurescriptsV. In addition, we collected qualitative feedback on patients’ Smart Pill Bottle usage through
structured interviews with 153 participants.
Results: Patients maintained an average adherence rate of 90.0% according to the smart pill bottle; however,
when dose misses were calibrated based on patient or provider feedback, the adjusted adherence was 93.6%.
Surescripts adherence rates for refills were 92.2%. Participants generally found the bottle easy to operate but
suggested that its size and functionality did not fit seamlessly into their existing routine, as many used weekly
pill organizers to manage multiple medications.
Discussion: Though each method of tracking adherence has positive and negative attributes, combining them
and seeking patient feedback may help capture a more accurate adherence rate than any single technological
intervention. Technologies may have different design considerations for research and consumer use.
Conclusion: Overall, these technologies provide useful but imperfect adherence data for research purposes,
and smart pill bottles could be improved with patient-centered design.
C

ABSTRACT
Lay Summary: Medication adherence is very important for those with chronic health issues. For those with
heart disease, medication adherence not only offers opportunities for improving quality of life, but it also can be
life-saving. Nonetheless, many patients with heart disease, including those with atrial fibrillation (the target
group for this study) do not take their medications regularly. As technologies advance, there is unprecedented
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opportunity to track patients’ medication adherence through various methods, which might provide motivation
and information to patients as they make daily choices about medication use. In this study, we cross-referenced
the results of two of these measures over 6 months—a smart pill bottle, which we used to track pill bottle openings, and e-prescribing software, which we used to track medication refills. We also supplemented these measures with nurse-patient communication via the EHR messaging portal to record exceptions (eg, travel and medication changes) and interviewed patients about their medication use during the 6-month trial. Overall, the
tracking technologies worked relatively well to track patient (n ¼ 160) medication behavior; however, they did
not capture exceptions. Hence, triangulating data from different sources, with a patient feedback loop, appears
critical for gathering accurate data on medication adherence.
Key words: medication adherence, atrial fibrillation, e-prescribing, electronic health record, remote sensing

Background and significance
Atrial fibrillation (AF) is the most common heart arrhythmia,1 predicted to affect 6–12 million Americans by 2050.2 Patients with AF
are typically prescribed oral anticoagulant (OAC) medication to reduce the risk of clot-related complications related to the arrhythmia;
however, nonadherence to these medications can have severe and
even fatal effects.3,4 AF contributes to least 1 in 6 strokes,5,6 which
tend to be more severe than strokes due to other causes7 and cost
over $8 billion per year,8 rendering OAC adherence in AF patients
both an individual and public health issue. The AF patient population generally consists of adults age 65þ,9 and AF-related knowledge among these patients if sometimes lacking.10
Medication adherence is a multifaceted process involving factors
like motivation, patient information, and learned behaviors.11 Research on technologies that support medication adherence, including
adherence among those with cardiovascular conditions, has flourished in recent years.12–19 These technologies track and/or support
adherence through a variety of mechanisms. One such technology is
electronic pill bottles, the newest versions of which can not only
track pill bottle openings, but also alert patients to missed doses and
remotely transmit signals so that clinicians can be alerted of such
misses.16,18,20,21 As their prices have become more affordable and
research has demonstrated their relative accuracy in tracking medication adherence, smart pill bottles are gaining popularity as a
mechanism for medication behavior change.22 Another innovation
is e-prescribing software, like Surescripts, which collects data on
patients’ medication histories and refills, which can be shared with
doctors, clinics, and pharmacists. Currently, Surescripts collects
medication history information from approximately 93% of insured
patients and 79% of the general US population.23 Through partnerships with EHR vendors, Surescripts feeds information directly into
many electronic health records (EHRs), which has expanded the opportunity for communication of medical histories across and within
platforms.24
These innovations were designed to help identify lapses in adherence by reporting information back to the patient either directly, or
indirectly through clinicians, in order to prompt behavior change.25
Although some studies reported marked increases of adherence with
the use of technology,13,15,26 others showed no significant effects.19
The reasons for these inconsistencies may be design issues,27 lack of
long-term engagement,19 and limitations in study methodologies.28
Even though the use of adherence technologies is generally considered more reliable than self-reports,16 they are often not nuanced
enough to capture when the use of the technology does not align
with the intended use (eg, when multiple doses are removed and

placed into an alternative pill sorter). Moreover, behavior change
might be limited when smart pill bottle remote transmissions or eprescribing medical history data are not sufficiently integrated into
clinical practice or shared back with the patient in a meaningful
way.
Recent research has attempted to explore the accuracy of these
technologies, showing that medication adherence rates vary depending on the way adherence is measured. In one study, although smart
pill bottle readings and pill counting were strongly and significantly
related, smart pill bottle readings were not strongly concordant with
plasma levels, and patients’ self-reports tended to overestimate their
adherence as compared to smart pill bottle readings.29 More recently, Mehta et al22 showed that for myocardial infarction patients,
higher rates of statin adherence were recorded when using medication refill information (72%) as compared to remote pill bottle
records (68%). However, notably, neither of these studies noted any
feedback loop between the clinician (or researcher) and the patients,
so it is unknown whether these adherence levels accurately reflect
true missed dosages. Moreover, no known studies have explored the
extent to which this feedback loop could prompt patient response,
which could potentially provide impetus for more sustained medication adherence tracking.

Objective
The remote monitoring feature of pill bottles paired with e-prescribing software offers an unprecedented opportunity to: (1) compare
adherence measures across these technologies and (2) examine the
extent to which patients are receptive and responsive to clinical feedback based on data from these technologies (ie, the feedback loop).
Building on past work on engaging cardiology patients with their
health data30–33 and taking into consideration the known issues associated with technology-driven medication adherence approaches,
we triangulated these adherence measures (smart pill bottle, medication refill information, and patient messages about missed doses).
We also created a feedback loop whereby nurses would provide information to patients when they missed doses. We also solicited AF
patient feedback via interviews regarding use of the smart pill bottle.
The associations between these three adherence measures are displayed in Figure 1.

METHODS
Adult AF patients receiving outpatient care within a mid-size Midwestern hospital system were recruited by research team members,
using referrals from cardiology clinic staff and chart review
(n ¼ 160). All participants had been prescribed a daily direct oral an-
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Figure 1. Feedback loop between adherence measures.

Figure 2. CONSORT diagram.

ticoagulant (DOAC) (Eliquis (apixaban) n ¼ 52; Xarelto (rivaroxaban) n ¼ 28) or warfarin (Coumadin n ¼ 80). (Pradaxa (dabigatran)
patients were excluded because Pradaxa (dabigatran) tablets should

be stored only in their original pill bottles to preserve the tablets.) As
part of a larger study evaluating the impact of tailored education on
medication adherence, patients were randomized into two groups
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Figure 4. Smart pill bottle dashboard utilized by research staff to record missed doses.

(see Figure 2). Data from both groups were analyzed for the current
study.

Medication adherence
Medication adherence was tracked via three methods, as described
below.

Smart pill bottle
Upon enrollment, daily dosage information, including usual medication schedule, was entered by research staff into the pill bottle software application, which was accessible only to the study team.
Participants were provided with the study personnel’s telephone
number and email address to communicate any medication or schedule change occurring throughout the study, and this was updated
immediately in the participant’s dashboard. All participants received
a Wireless Smart Pill Bottle by AdhereTech (Figure 3A) with alert
and reminder functionality (ie, lights/sounds for dosages due or
missed) disabled. The bottle’s sensors recorded doses as missed, late,

early, or on time, based on the date and time the participant removed and replaced the bottle cap, and this was displayed in a dashboard, inspected by study staff (see Figure 4). As many AF patients
take multiple medications, participants were instructed to use the
bottle for their OAC medication only. If the participant used a
weekly pill organizer, they were given Bingo chips to use as a visual
placeholder for their OAC in their own organizers but were still
instructed to keep their OAC medication in the smart pill bottle.

E-prescribing software
Pharmacy refill records were obtained directly from a Surescripts
data feed outside of the EHR (MyChart). This data feed (see
Figure 3B) was in .xml format, so was translated by business informatics staff into a simple status update (late or on time). These prescription refill data do have the ability to be pulled directly into an
EHR, but that was not done in this study. Instead, study staff
screened translated records weekly for alerts that prescription refills
for OACs or warfarin were overdue.
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Figure 3. (A) Smart pill bottle; (B) Surescripts.xml data feed; (C) sample reminder message sent by study staff based on alert.
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Patient experiences with pill bottle
We conducted 148 semi-structured face-to-face exit interviews with
participants (full interview n ¼ 70, abbreviated interview n ¼ 78); 12
participants did not complete exit interviews due to withdrawal,
death, or inability to contact. During the interview, patients were
asked details about their missed doses and any communication (or
lack of communication) with study staff. To aid their memory, research personnel showed patients logs of missed doses, Surescripts
data, and missed refill messages, if applicable. In addition, they were
asked about their experiences with the smart pill bottle. Interviews,
lasted approximately 20 min to 1 h, were held in a private room in
the research center, and were audio-recorded and transcribed for
analysis.

Data analysis
Quantitative
Of the 160 enrolled patients, 155 were included in quantitative analyses. Those that were excluded had missing or unreliable (due to
noncompliance with instructions) adherence data. We were interested in two main quantitative metrics: (1) adherence rates across
the two technologies (both raw, and, for the smart pill bottle, adjusted, supplemented by patient feedback and other notes within
EHR), and (2) messaging information (ie, messages sent to and from
patient via EHR) for medication adherence reconciliation. For the
smart pill bottles, the raw adherence rate was the ratio of doses that
were marked as taken (late, early, or on-time) relative to the scheduled doses the participant was ordered to take during the study period. We also calculated an “adjusted” score for pill bottle
adherence. For each dose marked by the pill bottle as missed, a clini-

cal nurse researcher inspected the EHR to determine if there were
documented, acceptable explanations as communicated from the patient via MyChart messages. These explanations were crossreferenced and supplemented with clinician notes from the EHR, or
records from the Anticoagulation Therapy Unit (ATU) Clinic. If
there was an acceptable reason noted for any of the doses marked as
missed by the smart pill bottle, this was documented as an “allowed
missed dose.” The allowed missed doses were subtracted from total
missed doses and the adherence percentage was recalculated.
Qualitative
An inductive thematic analysis was conducted with all interview
data. In this type of analysis, codes, or brief labels, are used to represent concepts identified in the qualitative data. The analysis team
members independently reviewed the same transcript and identified
concepts related to patients’ use of the smart pill bottle. For each
concept, a provisional code was created. The team members met to
compare codes, discuss discrepancies, and establish a final code set.
This iterative process continued until the set of codes was stable,
demonstrating conceptual saturation. Then, each transcript was
coded independently by two team members, who would meet to
compare codes and reach consensus. Team members were paired
with a new partner each week to prevent divergence in how codes
were applied. Data were coded using nVivo10 software. Once coding was complete, all data were aggregated and abstracted into summaries for each code.

RESULTS
Participants were 37.5% (60/160) female and 98.1% (153/156)
white with an average age of 71 years. Most had completed at least
some college (75.3%), were retired (73.0%), and lived with a spouse
or partner (77.9%). See Table 1 for complete participant demographics.

Medication adherence rates
Overall, 88% (141/160) participants had available Surescripts data
because they used a Surescripts enabled pharmacy, and 92.2% of
patients (130/141) were adherent with refilling their medication
over the 6-month project. Twenty percent (39/160) participants had
no Surescripts data available. Meanwhile, the raw smart pill bottle
average adherence rate was 90.0% (SD ¼ 10.8, see Table 2). In contrast, the adjusted pill bottle medication average adherence rate was
93.6% (SD ¼ 8.2). The distribution of these adjusted pill bottle adherence rates is displayed in Figure 5. In considering the difference
between these two rates for each participant, the range of discrepancies was 0.1% to 50.0%, with the raw adherence rates tending to
be lower than the adjusted rates (mean difference ¼ 3.6%;
SD ¼ 6.9). The average number of allowed missed doses was
8 (SD ¼ 19, median ¼ 1, range ¼ 0–133).

Messaging information
Of the 80 participants eligible to receive MyChart messages for
medication nonadherence alerts, a total of 138 messages alerting
about missed medication doses (triggered by smart pill bottle alerts)
were sent to 50 participants, and 45 messages alerting about missed
medication refills (triggered by Surescripts alerts) were sent to 18
participants. As some participants (n ¼ 13) received both smart pill
bottle and Surescripts triggered messages, 68.8% (55/80) participants in total received either smart pill bottle or Surescripts triggered
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Patient messages through EHR
Reconciliation of missed pills and refills was attempted via messaging to patients within the EHR (Figure 3C). At enrollment, participants received assistance in setting up their account if they were new
to MyChart, training on the general use of the EHR, and an interactive demonstration to show them how to access these messages on a
test account and view a sample message. Remote pill bottle transmissions were monitored daily (Monday–Friday) by the study team,
and one member of the study team alerted patients within 24 h following a patient missing a full day of their DOAC or two consecutive doses of warfarin. Patients received a second and third message
(both unique messages) via the EHR if they missed 2 d of OAC or 4
d of warfarin. In response to prescription refill alerts, study staff
sent messages to patients when their prescription refill was overdue
by at least a week. Patients who received messages from the study
team, triggered by smart pill bottle or Surescripts alerts, were
reminded of the importance of medication adherence and asked to
reply with explanations for missed doses and/or notify the study
team of upcoming doses that would be missed (ie, doctor ordered a
medication hold; patient leaving for vacation and bringing only their
weekly pill organizer). (Separate from these reminder messages, intervention group participants received weekly educational messages
as part of a separate hypothesis about the effect of educational interventions on medication adherence. Detailed descriptions of these
messages and the results of this intervention are described in other
work; the present study focuses on the methodology and feasibility
of capturing adherence via this multifaceted approach.) Patients
were also encouraged at enrollment to message study staff during
the course of the study if there were any changes or interruptions to
their medication schedule.
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Table 1. Participant demographics
Characteristic

Percent

37.5
62.5

60/160
100/160

1.3
11.3
31.3
46.3
9.4
0.6

2/160
18/160
50/160
74/160
15/160
1/160

98.1
0.6
1.3

153/156
1/156
2/156

13.8
5.0
1.9
5.7
73.0

22/159
8/159
3/159
9/159
116/159

3.3
21.4
29.9
25.3
20.1

5/154
33/154
46/154
39/154
31/154

5.4
22.8
24.2
24.8
9.4
13.4

8/149
34/149
36/149
37/149
14/149
20/149

16.5
77.9
5.1
0.6

26/158
123/158
8/158
1/158

Table 2. Means, minimums, and maximums for percentage of
medication adherence and adjusted medication adherence
(n ¼ 155)
Summary statistic

Mean adherence percentage
Minimum
Maximum

Pill bottle
adherence

Pill bottle
adjusted adherence

90.0
44.6
100.0

93.6
51.7
100.0

messages (M ¼ 3.3, SD ¼ 2.3, range ¼ 1–11). For both message
types, the number of responses from participants addressing the reason for the missed dose was recorded. As shown in Figure 6, regardless of the number of messages sent (1, 2 or 3, or 4þ), patients were
more likely to respond to none of the messages than to respond to at
least some messages. Overall, 65.5% (36/55) participants did not respond to any messages received. In addition, for 33.3% (16/48) of
those with nonresponse or partial response, one or more MyChart
messages were not read. However, 34.5% (19/55) did respond to
the EHR messages with explanations, and 20.0% (11/55) sent unsolicited messages to study staff with explanations for missed doses.

Figure 5. Distribution of adjusted adherence rates from smart pill bottle.

During the exit interviews, patients reflected on the impact of
the messaging with the study staff. When asked about the messages
sent, participants reflected positively, that “I was delighted that I
was told that I missed a dose. . .it put me right back on [my schedule]”
(P109). Patients reported they valued the human interaction with the
team via the communication feedback loop. Participants appreciated
the responsiveness, indicating that “she responded to me every time, every time she answered me” (P127). They also valued how the messaging
made them feel closer to the research as exemplified by P153: “I felt like
I was really part of the program. Knowing I could send her a message,
but not that she expected one all of the time.”

Patient experience with smart pill bottle
There were three main themes that emerged regarding patients’ experiences with the smart pill bottle technology, as described below.

Deviation from typical routine
Many participants already had a personalized medication routine,
using primarily event- or location-based cues (eg, a pill organizer on
their bathroom sink, taking pills with meals). Some easily integrated
the smart pill bottle into this routine, whereas others had complaints, with several specifically calling it “a pain.” In the former instance, a few participants noted that the bottle itself served as a
visual cue: “And it wasn’t an inconvenience for me. . .Because it was
there and it reminded me, when I looked at it, to take my pill”
(P40). Others commented that they felt the reminders from study
staff or the awareness of being monitored contributed positively to
their adherence. Among those who did not find the bottle to be convenient, a common complaint was that it was an extra, unnecessary
step: “I had to be a little extra diligent because I um, I have two pill
boxes and usually my pills are right in there with my daily pills, so it
was like I had a third schedule that I had to keep track of” (P94).
Some participants modified this additional step by continuing
their prior routine (eg, weekly pill organizer), but also opening the
smart pill bottle lid: “When I took my Coumadin, I took the lid offCounted to 3. Put the lid back on” (P101). Although this allowed
these participants to maintain their routine while also contributing
adherence data, they reported sometimes forgetting to open the lid
or being away from the bottle when taking their medication. This
method was also used to mitigate the inconvenience of storing half
and whole tablets in the same bottle when patients’ dosing routine
required both. Compared to a weekly pill organizer, patients felt it
was difficult to locate and retrieve the half tablets, as well as remember which size tablet was due.
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Gender
Female
Male
Age
41–50
51–60
61–70
71–80
81–90
91–100
Race
White
Asian
Other
Employment status
Employed full time
Employed part time
Unemployed
Disabled/unable to work
Retired
Education level
Did not graduate high school
High school graduate/GED
Trade/some college
College graduate
Postgraduate degree
Annual income
Less than $20,000
$20,000–40,000
$40,001–60,000
$60,001–80,000
$80,001–100,000
Over $100,000
Household occupants
Alone
With a spouse or partner
With a family member
With a friend

Count
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Possible misinterpretation of missed doses
Many patients expressed surprise or disbelief when initially presented with the number of missed doses. Though some eventually
agreed or presented verifiable explanations, some felt adamantly the
data were inaccurate, without suggestions for where the discrepancy
originated. “There ain’t no way I missed that many pills. I don’t
think I missed any” (P67). Others were more unsure, but still did
not feel that their adherence was as poor as the data indicated:
“Mmm, I don’t know, I guess I don’t think I missed that many. I
might have missed one or two” (P39). Others reported technical
issues with the bottle (“I know there was times that the light didn’t
come on when I opened and closed it” [P12]). Some conjectured that
their data were tracked incorrectly due to a change in dosage frequency: “They switched my medication and I thought I had told her
that. . .So I’m sure lots of those days are because they thought I was
supposed to take it twice a day” (P19). As was investigated in our
analysis regarding discarded doses, some suggested that inaccuracies
may have occurred due to technicalities regarding timing (too close
together or far apart) or time of day (eg, taking an evening pill after
midnight).

Features of the physical bottle
Some participants found the bottle easy to use and/or effective for its
intended purpose—for example, P98, who “looked at the bottle as a
fun project.” However, other participants frequently noted that its
size and bulkiness was inconsistent with their existing routine and
created issues with storage and travel. P24 stated, “The only thing I
found that was inconvenient, when I was traveling or if I was gonna
go out at night and I left early and I couldn’t take, you know, I took
the pills out of there, you know and put them in my purse. . . I didn’t
want to carry the big thing with me.” Many participants preferred a
weekly pill box that allowed them to organize multiple pill sizes or
types: “I like my pill box better. . .just because I take other medication. So I wouldn’t have to have two things, I could just have that”
(P7). “And I’ll be honest with ya, if they ever do another study like
this, try to come up with a uh, like a weekly container or something”
(P27). Another issue of particular concern in an older population
was the lid—multiple participants noted that it did not always screw
on easily or correctly, and they worried that it would not record accurate dosing because of this: “Well, I’ve got some arthritis. . .. And

especially in the morning it’s very noticeable and sometimes I just
don’t think I got it threaded properly” (P92). Patients also offered
suggestions for features the bottle has when used in the “real world”
(ie, real-time text alerts), as well as features for future improvement,
such as an interactive bottle that could be asked questions (like Amazon Alexa or Google Home) or programmed for travel or dosage
adjustments.

DISCUSSION
These findings support the oft-cited challenges of accurately documenting medication adherence. Although new devices and technologies have provided novel methodologies by which to triangulate this
important data point, each method has pros and cons. In terms of
pros, both Surescripts and the smart pill bottle software reported
rather high (and similar) adherence rates in our sample of AF
patients (90.0% and 88.8%, respectively). These adherence rates are
higher than those often reported via interview or survey among
chronic illness patients (ie, 50–70%).34,35 In addition, both tools
could prompt reminders or provider contact, which might influence
adherence behavior. However, both of these technologies had limitations in terms of accuracy and practicability. For example, the
Surescripts data were available for only 88% of patients in our sample, which limits its utility in both research in practice. Moreover, it
remains a more distal and indirect measure of adherence than the
smart pill bottle, which recorded patients’ daily medication activity.
The smart pill bottle, however, was also an imperfect measure of adherence. Based on data from other sources, including patient messages and provider notes, the smart pill bottle underestimated
patients’ medication adherence rates (90.0% raw vs 93.6% adjusted). Although the smart pill bottle is a more direct measure of
medication-taking behavior than retrospective self-reporting or
pharmacy refill records, it also does not account for valid “missed”
doses where patients are asked to temporarily discontinue their medication or choose to transfer pills to another container. This finding
is important, as it emphasizes the need for a feedback loop between
patients and providers regarding medication adherence and highlights the potential for the EHR and patient portals to be sources of
verification for data gathered from remote technology.
Our feedback loop via the EHR was only somewhat effective for
verifying adherence, as the study team was able to reach and receive
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Figure 6. Percentage of patients (n ¼ 80) who responded to EHR alert messages based on number of total messages sent (1, 2 or 3, or 4þ).
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routines, how adaptable it is for exceptional circumstances (eg,
travel, existing weekly pillbox, changes in medication regiment,
etc.), and how practicable the device is for general usage.
Overall, our study suggests that triangulating data from different
sources, including a patient feedback loop, is critical for gathering
accurate data on medication adherence. This is important for both
research and practice, providing a method for increasing methodological rigor and effective communication between patients and providers. Meanwhile, our interview data suggest that more research
into the daily integration of smart pill bottles in the routines of
chronically ill patients is necessary. Specifically, future research
should explore how to seamlessly integrate monitoring and alert
technology into the external memory aids patients are already using
in their daily lives (eg, pill sorters and mobile phones). Technologies
external to these working systems may be seen as additional burdens
to those already battling a chronic illness.

Limitations
Our study does have limitations that need mention. First, although
we reported “adherence rates,” the Surescripts and smart pill bottle
data do not necessarily reflect true adherence rates, as we cannot be
sure that the patients were actually ingesting the medication that
they filled or removed from the bottle. Similarly, our method of validating “allowed misses” relied on patient self-report and doctors;
notes, which may not have been accurate. However, we crosschecked all provider-involved explanations with EHR documentation and/or ATU clinic records, and for explanations that involved
only the patient (ie, traveling with only one pill container for all
medications), we elicited additional feedback through patient portal
messages and during the exit interview. This method, of course, is
not foolproof, as there is no way to guarantee patients actually took
their OAC during these self-reported routine changes. Conversely,
to ignore these explanations of missed doses would be willfully disregarding patient feedback regarding their own medication practices. Regarding this patient feedback, we did not directly address the
value of the messaging to the patients in our exit interviews. Although they provided comments on the value of the messaging, we
missed an opportunity to explore why participants did not respond
to messages. In addition, we did not explore in interviews how personal factors (eg, patients’ desire to limit medication consumption)
or patient ergonomic factors in the home environment might influence medication adherence. As both personal and ergonomic factors
might influence future designs of digital technologies, these are valuable avenues for future research. With regard to our sample, we
were unable to include patients taking all available OACs, such as
PradaxaV (dabigatran), and while our sample was fairly representative of the rural and suburban geographic area from which participants were recruited, it was ethnically homogenous. Also, all
patients enrolled in this study needed to have access to the computer
and Internet to be enrolled in the study. This may have led to a selection bias whereby those who were most ill (and perhaps least adherent to medications) may not have been included in the study.37
These results need to be interpreted with these limitations in mind.
R

CONCLUSION
With increased availability of smaller and inexpensive sensor technology and the integration of e-prescribing software into the EHR,
several options exist to enable remote tracking of patients’ medication adherence, which can help to prevent serious health risks and
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responses from only a small percentage of participants. Many participants (65.5%) did not respond to messages, a trend that persisted
regardless of the number of messages sent (1 to 4þ). More troubling,
of those nonresponders, a sizeable minority (33.3%) did not read all
messages. This could imply a lack of commitment to medication adherence or a lack of engagement with the communication medium
(or a number of other motivational factors). With regard to limitations of the medium, it required participants to access messages
within EHR, which although we gave training on the system, lack of
familiarity with the system or lack of Internet access may have contributed to low response rates. Furthermore, our EHR-based method
of alerting patients to missed doses or refills (ie, receiving the pill
bottle and Surescripts data through external software and data pulls
and then messaging patients) was laborious and time-lagged. This
intensive surveillance monitoring from a clinical team is not practicable in the long term as it is cost- and time-intensive. Instead, an integrated platform (ie, automated messages triggered by having both
types of software integrated into the EHR) or a fully functional
smart pill bottle could have provided more immediate feedback. Interestingly, many patients suggested that features already present
when the smart pill bottle is used as designed (eg, receiving missed
dose alerts via text message) would help them see alerts within an
actionable timeframe because the alert would be immediate and delivered via technology they already use daily (ie, a cell phone). Furthermore, if the patients themselves have access to these integrated
dashboards, they could update the software on missed doses, medication changes, and other exceptions to medication schedules, which
may help to increase personal agency and adherence rates overall. In
short, as it exists currently, the patient EHR portal has shortcomings
as a medication adherence feedback tool; however, there is promise
for medication adherence technologies that are designed to be more
accessible, transparent, and user-friendly. Moreover, as these technologies move toward integration into the EHR, it will be important
for researchers and clinicians to understand that each technology
might capture a slightly different view of the medication adherence
picture.
In addition to accuracy concerns when using technology to measure medication adherence, the pill bottle itself posed some challenges to users. These challenges, emerging from interview data,
include disruptions to existing medication routines and design shortcomings. Like many AF patients, participants in our study often
took medications in addition to their OAC and used a pill organizer
to manage this. Some patients found it fairly easy to integrate the
smart pill bottle into this routine (ie, keeping it in the same location
as their pill organizer), whereas others felt it was an unnecessary
added step or that the bottle was too large or bulky to be convenient. In addition, some patients’ routines involved taking half tablets at times, and this was difficult to execute and track with just one
bottle. Finally, despite the manufacturer of the smart pill bottle stating that the average user age is 70,36 some patients found the bottle
difficult to use, noting that they sometimes had trouble with the
physical motion of removing or replacing the lid, and expressing
worry that this may affect accurate recording of their adherence.
This issue could be mitigated with re-designs that consider ease of
use among elderly patients or more upfront education (by clinical or
study staff) on proper use. For current research and design efforts, it
is critical for stakeholders to consider how personal and patient ergonomic factors might affect their adoption and use of smart medication technologies. Before technologies are dispersed to the general
public, it is important to conduct pilot studies on their actual longterm use, measuring how that technology fits into patients’ current
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increased health care costs resulting from missed medication. However, as our study showed, remote monitoring is not a panacea for
either tracking medication adherence accurately or for prompting
behavior change. As medication adherence is crucial for long-term
wellness and survival of those with chronic illnesses, a multipronged
approach, including a patient feedback loop regarding adherence
and the integration of technologies into daily lives, appears critical.
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